Advances in the pathogenesis of FLT3 -mutated acute myeloid leukemia and targeted treatments

purpose of reviewFLT3 mutations are among the most common myeloid drivers identified in adult acute myeloid leukemia (AML). their identification is crucial for the precise risk assessment because of the strong prognostic significance of the most recurrent type of FLT3 alterations, namely internal tandem duplications (ITDs). recent advances in the pathogenesis and biology of FLT3-mutated AML have opened an opportunity for development and application of selective inhibition of FLT3 pathway. recent findingsIn the last decade, at least three targeted treatments have been approved by regulatory agencies and several others are currently under investigations. here, we review the latest advance in the role of FLT3 mutations in AML, providing an outline of the available therapeutic strategies, their mechanisms of actions and of resistance, as well as routes for potential improvement. summary the availability of FLT3 inhibitors has improved outcomes in AML harboring such mutations, currently also reflected in disease stratification and recommendations. newer inhibitors are under investigations, and combinations with chemotherapy or other targeted treatments are being explored to further improve disease outcomes.